Definium Therapeutics, Inc. 8-K

What Happened

• Definium Therapeutics, Inc. (DFTX) announced its financial results for the fiscal year ended December 31, 2025, and provided information about a conference call to discuss those results and recent corporate highlights. The company issued a press release on February 26, 2026, which is furnished as Exhibit 99.1 to the Form 8-K (Item 2.02).

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Reporting: Financial results covered for fiscal year ended December 31, 2025 (press release contains the detailed figures).
• Disclosure: Press release is furnished as Exhibit 99.1 to the Form 8-K (Item 9.01 lists the exhibit).
• Signature: Report signed by CEO Robert Barrow on February 26, 2026.

Why It Matters

• This 8‑K signals that Definium has published its full-year 2025 earnings and will host a call to discuss performance and highlights — key sources for investors to assess revenue, expenses, cash position, and management outlook.
• The Form 8‑K itself does not include the financial figures; investors should review the attached press release (Exhibit 99.1) and listen to the company’s conference call for the detailed earnings, any guidance, and management commentary that could affect the stock.